Introduction
Material and methods
Patients
Hearing and visual assessment
Imaging
Laboratory tests
Mutation analysis
Statistical analysis
Standard protocol approvals, registrations and patient consents
Results
No. 1(A) | No. 2 | No. 3(A) | No. 4 | No. 5 | No. 6 | No. 7 | No. 8(B) | No. 9(B) | No. 10 | No. 11 | No. 12 | No. 13(C) | No. 14 | No. 15 | No. 16(C) | No. 17 | No. 18a
| No. 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mutations | |||||||||||||||||||
Allele 1 | P1c.2528G> | P1c.2528G>A | P1c.2528G>A | P11Bc.64C>T | P26c.292C>T | P1c.2528G>A | P1c.1777G>A | P1c.2528G>A | P1c.2528G>A | P6c.1801C>T | P1c.2528G>A | P26c.292C>T | P1c.2528G>A | P1c.2528G>A | P1c.2528G>A | P1c.2528G>A | P1c.2528G>A | P1c.2528G>A | P1c.2528G>A |
Allele 2 | P1c.2528G> | P1c.2528G>A | P1c.2528G>A | P11Bc.64C>T | P26c.292C>T | P1c.2528G>A | P1c.2071+1G>T | P1c.2528G>A | P1c.2528G>A | P6c.1992G>C | P1c.2528G>A | P26c.292C>T | unknown | P1c.2528G>A | P1c.2528G>A | unknown | P1c.2636 T>C | P1c.2097insT | P1c.2528G>A |
Age at latest visit (yrs) | 35 | 32 | 31 | 27.5 | 23 | 22 | 19.5 | 19 | 17.5 | 17.5 | 17 | 16 | 28 | 27 | 24.5 | 22 | 18.5 | 18 | 17 |
Age at diagnosis (yrs) | 5 | 31 | 0.25 | 25 | 6 | 2 | 0.25 | 3.5 | 3 | 3 | 8 | 4 | 0.5 | 0.75 | 0.02 | 0.02 | 1.3 | 0.5 | 5 |
Presenting symptoms | |||||||||||||||||||
Failure to thrive | + | + | + | + | + | ||||||||||||||
Bilateral 4-fingerline | + | + | + | ||||||||||||||||
Hearing impairment | + | + | + | + | + | + | + | + | |||||||||||
Hypotonia | + | + | + | + | |||||||||||||||
Jaundice | + | + | + | + | + | + | + | ||||||||||||
Visual impairment | + | + | + | + | + | + | + | + | + | + | + | + | |||||||
Facial dysmorphia | |||||||||||||||||||
Attached earlobes | + | + | + | + | + | + | + | + | + | + | + | + | |||||||
Epicanthal folds | + | + | + | ||||||||||||||||
High forehead | + | + | + | + | + | + | |||||||||||||
Speech development | |||||||||||||||||||
Absent | + | + | + | + | + | + | |||||||||||||
Short sentences | + | + | + | ||||||||||||||||
Sufficient working vocabulary | + | + | + | + | + | + | + | + | + | + | |||||||||
Intellectual disability | moderate | moderate | moderate | moderate | moderate | moderate | moderate | moderate | moderate | moderate | none | moderate | severe | severe | severe | severe | severe | severe | severe |
Age of examination in yrs | 7 | 32 | 18 | 11 | 15 | 5 | 6 | 14 | 9 | 15 | 9 | 15 | 9 | ||||||
Total IQ | 54 | 67 | 64 | 60 | |||||||||||||||
Verbal IQ | <55 | 54 | 67 | 105 | |||||||||||||||
Non-verbal IQ | 60 | 54 | 59 | 83 | |||||||||||||||
Developmental level in yrs | 2.5 | 7 | 2.5 | 1 | 2 | ||||||||||||||
Residence | |||||||||||||||||||
Assisted living facility | + | + | + | ||||||||||||||||
Parental home | + | + | + | + | + | + | + | + | |||||||||||
Parental home with continuous supervision | + | + | + | + | + | ||||||||||||||
nursing home | + | + | + | ||||||||||||||||
Education | |||||||||||||||||||
Higher vocational education | + | ||||||||||||||||||
Sec. vocational education level 1b
| + | + | |||||||||||||||||
Special education cluster 2c
| + | + | + | + | + | + | |||||||||||||
Special education cluster 3d
| + | + | + | ||||||||||||||||
Supported employment e
| + | + | + | + | + | + | + | ||||||||||||
Miscellaneous | EH | EH | EH | EH | EH | EH, explicit memory at a normal level | EH | EH, able to cope with money, drives a scooter | EH, drives a bicycle | EH | EH, completely normal gait | EH, able to cope with money | EH | EH, examined during house call | EH | EH, PEG tube (at 7 years of age) | EH | EH, PEG tube (at 5 years of age) | EH |
Nervous system | No. 1 (A) | No. 2 | No. 3 (A) | No. 4 | No. 5 | No. 6 | No. 7 | No. 8 (B) | No. 9 (B) | No. 10 | No. 11 | No. 12 | No.13(C) | No. 14 | No. 15 | No. 16 (C) | No. 17 | No. 18a
| no. 19 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Visual system | |||||||||||||||||||
Cataract | + | + | |||||||||||||||||
Retinitis pigmentosa | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | + | |||
Visual acuity scalesb
| 0.33 | 0.05 | 0.08 | 0.1 | 0.11 | 0.1 | 0.1 | 0.2 | 0.25 | 0.25 | 0.25 | 0.15 | 0.2 | 0.05 | 0.04 | <0.1 | 0.1 | 0.05 | |
Stable/progressive | = | ↓ | ↓ | ↓ | = | = | = | = | = | = | = | = | = | = | = | = | ↓ | = | |
VEP, age at examination in yrs | 30 | 26 | 18 | 2 | 14 | 13 | 4 | 11 | 11 | 1 | 5 | 1 | |||||||
Flash | normal | PL | PL | normal | PL | DL | PL | PL | PL | poor pattern | |||||||||
Pattern | PL | PL | PL | DL | DL | PL | |||||||||||||
Hearing system | CI | ||||||||||||||||||
Hearing loss (dB),left/right | 80 | 90/110 | 80/75 | 80 | 85 | 70 | 90/90 | 80 | 95 | impossible to asses | |||||||||
Low frequency | 60 | 80 | 75 | 40 | 80 | ||||||||||||||
High frequency | 110 | 80 | 75 | 110 | 80 | ||||||||||||||
Stable/progressive | = | = | = | ↓ | ↓ | = | = | = | = | = | = | ↓ | = | = | = | = | |||
BAEP, age at examination in yrs | 30 | 26 | 18 | 14 | 13 | 11 | 11 | 2 | 1 | 2 | |||||||||
Absent | + | + | + | + | + | + | + | + | |||||||||||
Normal | + | + | |||||||||||||||||
Motor and sensory system | CS, PS | PN | CS, PN, PS | CS, PS | CS | CS, PN | CS, PN | CS | PN | PS | CS, PN | PS | CS, PN, PS | ||||||
Ataxia | + | + | + | + | + | + | + | ||||||||||||
Babinski | + | + | + | + | + | ||||||||||||||
Brisk reflexes | + | + | + | + | + | + | |||||||||||||
Clonus | + | + | |||||||||||||||||
Dysarthria | + | + | + | + | |||||||||||||||
Dysmetria | + | + | + | + | |||||||||||||||
Intention tremor | + | + | |||||||||||||||||
Nystagmus | + | + | + | + | + | + | + | + | |||||||||||
Absent reflexes | + | + | |||||||||||||||||
Clawfeet | + | ||||||||||||||||||
Contractures ankles/knee | + | + | |||||||||||||||||
Hammertoes | + | + | + | + | |||||||||||||||
Muscular atrophy | + | + | + | + | + | + | + | ||||||||||||
Pes cavus | + | + | + | + | + | + | + | ||||||||||||
Other signs | absent vibration sense | steppage gait | unable to walk | no reaction upon pain stimuli | |||||||||||||||
NCS, age at examination in yrs | 30 | 16 | 18 | 14 | 11 | 4 | |||||||||||||
Normal | + | + | + | + | |||||||||||||||
Sensory responses | |||||||||||||||||||
Demyelinating PN | + | + | |||||||||||||||||
Other systemic features | LC | LC | LF | AI, HM, KS, LC, SM | |||||||||||||||
Maximal motor skills | |||||||||||||||||||
Wheelchair-bound | + | + | + | + | + | + | |||||||||||||
Sitting | + | + | + | ||||||||||||||||
Walking with support | + | + | |||||||||||||||||
Walking | + | + | + | ||||||||||||||||
Running | + | + | + | + | + | + | + | + | + | + | + | ||||||||
Disease course in recent years | = | = | = | ↓ | ↓ | ↓ | = | = | ↓ | = | = | = | = | = | = | ↓↓ | ↓ | ↓↓ | = |
Clinical deterioration/age in yrs | PN/26 | ataxia/15 | ataxia/16 | in MF/16 | in MF/12 | in MF/16 | in MF/14 |
Clinical features
Activities of daily living
MRI findings
Patients no. | Age at MRI, yrs | White matter hyperintensitya
| Cerebellar cortical atrophy | ||
---|---|---|---|---|---|
Cerebral hemispheres | Cerebellum | ||||
HDN | WM | ||||
1 | 14 | ─ | ─ | ─ | ─ |
21 | ─ | ─ | ─ | ─ | |
30 | ─ | ─ | ─ | ─ | |
2 | 32 | ─ | + + | + + | ─ |
3 | 10 | ─ | ─ | ─ | ─ |
16 | + | + | + | ─ | |
25 | + + | + + | + | + | |
4 | 12 | ─ | ─ | ─ | ─ |
5 | 7 | ─ | + | + | + |
13 | ─ | + | + | + | |
21 | ─ | ++ | + | ++ | |
6 | 0.5 | ─ | ─ | ─ | ─ |
2 | ─ | ─ | ─ | ─ | |
4 | ─ | + | ─ | ─ | |
11 | + + | + + | ─ | ─ | |
14 | +++ | +++ | + | ─ | |
17 | ++++ | ++++ | ++ | ─ | |
18 | +++++ | +++++ | +++ | ─ | |
22 | +++++ | +++++ | ++++ | ─ | |
7 | 14 | ─ | ─ | ─ | ─ |
8 | 4 | ─ | ─ | ─ | ─ |
13 | ─ | + | ─ | + | |
17 | ─ | + | ─ | + | |
9 | 3 | ─ | ─ | ─ | ─ |
6 | ─ | ─ | ─ | ─ | |
13 | ++ | ++ | ++ | ─ | |
16 | ++ | ++ | ++ | ─ | |
10 | none | ||||
11 | 3 | ─ | ─ | ─ | ─ |
15 | ─ | ─ | ─ | ─ | |
12 | 6 | ─ | + | ─ | ─ |
11 | ─ | + | ─ | ─ | |
16 | ─ | + | ─ | ─ | |
13 | none | ||||
14 | none | ||||
15 | 1 | ─ | ─ | ─ | ─ |
16 | 7 | ─ | ─ | ─ | + |
17 | 7 | + | + | ─ | ─ |
18 | 1 | ─ | ─ | ─ | ─ |
17 | ─ | ─ | + | + | |
19 | 3 | ─ | ─ | ─ | ─ |
9 | ─ | ─ | ─ | + |
Laboratory tests
Patient 1 (A) | Patient 2 | Patient 3 (A) | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 (B) | Patient 9 (B) | Patient 10 | Patient 11 | Patient 12 | Patient 13 (C) | Patient 14 | Patient 15 | Patient 16 (C) | Patient 17 | Patient 18 | Patient 19 | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Age, yrs | Ref. range | 12a
| 35b
| 31a
| 33b
| 8a
| 31b
| 26a
| 27.5b
| 8a
| 23b
| 1.6a
| 23b
| 4a
| 19.5b
| 4a
| 19b
| 4a
| 17.5b
| 3.5a
| 17.5b
| 8a
| 17b
| 5.5a
| 16b
| 11.5a
| 28b
| 8.5a
| 18b
| birtha
| 24b
| 1a
| 22b
| 1.5a
| 16b
| 0.5a
| 18b
| 5a
| 17b
|
Plasma | |||||||||||||||||||||||||||||||||||||||
C22:0, μmol/l | 40-119 |
14
| 26.2 | 51 | 72.5 |
9.6
|
38.2
| 65 | 53.34 |
36
|
27.4
|
12.1
| 77.1 |
18
|
34.59
| 54.5 |
31.6
| 42.78 |
17.2
| 40.18 | 46.8 | 61.7 |
16
|
20.3
| 45.8 | 56.4 |
19.7
|
38
|
19
| 94.2 |
10.5
|
31.6
|
15
|
32.2
| 76 |
22.7
|
29
| 49.6 | |
C24:0, μmol/l | 33-84 | 37 |
45
| 57.3 |
44.3
| 75.6 | 48.8 | 37 |
29.5
|
17.1
| 78.8 |
21
| 39.93 | 34 | 57.9 | 40.2 | 48.31 |
18.2
| 37.84 | 47.4 | 58.9 |
14
|
25.2
| 44.5 | 65.5 | 45 | 39 |
32
| 84.1 |
19.7
|
29.3
|
22
| 34.5 | 33.9 | 39 | 54.8 | |||
C26:0, μmol/l | 0.45–1.32 | 0.5 |
3.31
|
2.2
| 0.73 | 0.5 | 1.16 | 1.3 |
1.38
|
4
|
2.73
|
2.78
|
3.51
|
1.5
|
1.67
|
1.8
|
1.63
|
3.01
|
2.35
|
1.63
|
1.33
|
1.91
| 1.28 |
1.47
|
1.43
|
2.64
|
4.72
|
1.38
|
1.9
|
2.8
|
2.44
|
3.15
|
2.4
|
5.6
|
3.16
| 0.89 |
4.63
|
3.3
|
4.17
|
C26:0/C22:0, ratio | 0–0.02 |
0.04
|
0.13
|
0.04
| 0.01 |
0.05
|
0.05
| 0.02 |
0.03
|
0.11
|
0.1
|
0.23
|
0.05
|
0.08
|
0.05
|
0.03
|
0.1
|
0.05
|
0.1
|
0.03
|
0.04
| 0.02 |
0.09
|
0.07
|
0.06
|
0.08
|
0.07
|
0.05
|
0.15
|
0.03
|
0.3
|
0.08
|
0.36
|
0.1
| 0.01 |
0.2
|
0.11
|
0.08
| |
CA, μmol/l | 0.1–4.7 | 0.8 | 0.8 | 0.6 | 0.1 | 1.7 | 2.6 | 1 |
10.7
| 0.5 | 1.5 | 0.1 | 2.9 | 1 | 0.8 | 2 | 1.2 | 0.4 |
6.7
| 0.3 | 1.9 | 1.4 | 2.6 | 0.8 | 1.7 | 1.4 | 3.6 | 1.5 |
10.9
| 1.4 | 2.5 | 1.5 |
32
|
48.2
|
6.3
| 0.6 | |||
CDCA, μmol/l | 0.7–10 | 2.6 | 3.6 | 2 | 0.6 | 0.6 | 0.2 | 0.3 | 4.2 | 1.3 |
12
| 0.3 | 0.4 | 5.4 | 3 |
11.5
| 4.1 | 1.5 | 3.3 | 0.6 | 10 | 4.8 | 0.4 | 0.2 | 0.7 | 0.6 | 2.8 | 0.6 | 3.3 | 1.5 | 8.4 | 6.8 | 5.5 | 8.2 |
14
| 0.9 | |||
DHCA, μmol/l | 0 |
0.2
|
1.6
| 0 | 0 |
0.2
|
0.3
| 0 | 0 |
10
|
3.1
|
0.5
| 0 |
6.1
| 0 |
1.1
| 0 |
0.6
| 0 |
0.9
| 0 |
0.4
| 0 |
22.4
|
2.8
|
2.3
|
0.1
|
0.1
| 0 |
0.3
|
0.1
|
2.9
|
1.2
|
6
|
2.2
|
47
|
4.5
|
1.2
| 0 |
THCA, μmol/l | 0–0.1 |
0.2
|
0.9
| 0 | 0 |
0.3
| 0.1 | 0 | 0 |
1.9
|
1.2
|
0.4
| 0 |
6.2
| 0 |
0.6
| 0.1 |
0.3
| 0.1 |
1.7
| 0.1 |
1.9
| 0 |
15.1
|
7.2
|
1.8
| 0.1 | 0.1 | 0.1 |
10.3
|
0.1
|
9.5
|
0.2
|
3.5
|
1.1
|
334
|
7.4
|
2.2
| 0 |
C29, μmol/l | 0 |
0.1
| 0 | 0 | 0 | 0 |
1.7
|
0.2
|
0.3
| 0 |
1.2
| 0 |
1.2
| 0 |
0.1
| 0 |
0.1
| 0 |
0.1
| 0 |
0.4
|
0.1
|
0.9
| 0 | 0 | 0 |
4.4
| 0 |
2.3
|
0.1
|
25
|
0.3
|
0.3
| 0 | |||||
Pipecolic acid, μmol/l | 0.5–9.9 |
10.8
|
20.4
| 3.5 | 1.4 | 1.8 |
38.6
|
500
| 2.9 |
111
| 3 | 3.7 |
13.7
| 7.6 |
33.6
|
10.2
|
10.5
| 5.5 |
36.1
|
46.1
|
15.8
|
32
|
21.4
| 3.3 |
14.1
| 2.9 |
14.7
|
283
|
10.7
|
230
|
53.3
|
27
|
13
| ||||||
Pristanic acid, μmol/l | 0.1–3 | 2.6 |
4.3
| 2.9 | 0.2 |
5.5
| 0.9 | 0.6 | 0.5 |
26
|
7.7
| 0.8 | 2 | 0.3 |
21
| 0.6 |
3.2
| 1.5 | 0 | 1.1 |
16.6
| 0.1 |
16.7
|
15.9
|
6
|
5.4
| 0.2 | 0.4 | 2 | 0.8 |
44
| 2.9 | 2.6 | 0.4 |
9.7
|
7.9
| |||
Phytanic acid, μmol/l | 0.1–7 |
4.4
|
10
|
6.6
| 2.2 |
8.4
| 1.2 | 4.6 | 4 |
98
|
27.6
| 1 | 4.2 |
14
| 1 |
49
| 4.5 |
11
|
7.4
|
10
| 3.2 |
36.1
| 0.9 |
68.8
|
55.9
|
77
|
25.4
| 3.5 | 1.1 | 2 | 5.9 | 2.6 | 6.3 |
170
|
11.5
|
7.9
| 3.9 |
30
|
13
|
AST, U/L |
c
| 23 | 35 | 24 | 29 | 24 | 30 | 55 |
58
| 38 | 77 | 30 |
58
| 31 |
62
| 29 | 33 |
60
| 24 |
50
| 28 |
59
|
43
|
97
| 30 |
121
| 23 |
47
|
54
|
58
|
54
|
58
| 36 | ||||||
ALT, U/L |
d
| 27 | 25 | 29 | 33 | 17 |
48
|
124
| 34 | 40 |
56
| 27 |
27
| 20 | 27 | 30 | 16 | 17 | 25 | 14 |
48
| 18 | 35 | 34 | 25 |
50
| 34 |
74
| 20 | 26 | 35 | 37 | 16 | 25 | 31 | ||||
Gamma-GT |
e
| 27 |
55
| 18 | 52 | 22 | 28 | 30 | 18 | 31 | 19 | 18 | 14 | 7 | 14 | 16 | 23 | 28 | 60 | 17 | 58 | 31 |
45
| ||||||||||||||||
Erytrocytes | |||||||||||||||||||||||||||||||||||||||
C16:0 DMA | 6.8–11.9 % | 7.9 |
6.2
| 6.8 | 8 | 6.9 |
4.9
|
5.7
| 8.2 | 9.2 |
1.5
| 7.3 | 7.3 | 7.6 | 8.4 |
6.3
| 7.6 | 7.5 | 9.6 |
6.4
| 7.5 |
6.5
| 7.7 | 7.2 | 9.4 | 7.9 | 8.7 |
6.7
|
4.3
| 8.3 |
6.5
|
6.6
|
5.2
| 8 | 7.3 | ||||
C18:0 DMA | 10.6–24.9 % | 16 | 14.7 | 18.8 | 16 | 15.8 | 12 | 12.2 | 18 | 22.4 |
7.9
| 19.6 | 17 | 15.5 | 21 | 15.4 | 17.9 | 17.7 | 18.3 | 17.1 | 20 | 16.3 | 17.9 | 17.1 | 21.2 | 19.9 | 17 | 16.8 |
9.3
| 18 | 15.3 | 11.3 |
10.1
| 17 | 19.4 | ||||
Urine f
| |||||||||||||||||||||||||||||||||||||||
Oxalic acid | 0.02–0.06 |
0.06
|
0.06
| 0.05 | 0.02 | 0.04 | 0.01 | 0.11 | 0.01 |
0.16
| 0.02 |
0.1
| 0.04 |
0.09
| 0.03 | 0.06 |
0.08
|
0.15
|
0.1
| 0.04 | |||||||||||||||||||
Glycolic acid | 20–140 | 115 | 120 | 139 | 60 | 124 | 58 | 199 | 102 | 34 |
261
|
209
| 118 |
266
|
356
| 70 | 126 |
286
|
231
|
Ref. range | No. 1 (A) | No. 2 | No. 3(A) | No. 4 | No. 5 | No. 6 | No. 7 | No.8 (B) | No. 9 (B) | No. 10 | No. 11 | No. 12 | No.13 (C) | No. 14 | No.15 | No.16 (C) | No.17 | No. 18 | No. 19 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Fibroblasts | ||||||||||||||||||||
C22:0, μmol/g protein | 3.84–10.20 |
3.02
|
2.76
| 5.47 |
2.36
|
3.35
| 4.67 |
3.01
|
3.6
| 4.17 | 5.18 |
3.33
|
2.9
|
2.73
| 5.45 |
2.91
|
3.68
| |||
C24:0, μmol/g protein | 7.76–17.66 |
7.68
| 8.8 | 11.04 |
5.41
| 8.74 | 8.64 | 13.16 | 11.16 | 9.59 | 14.14 | 8.46 | 8.66 |
6.12
| 12.48 | 8.37 | 10.64 | |||
C26:0, μmol/g protein | 0.18–0.38 |
0.76
|
1.25
| 0.27 |
1.23
|
0.98
|
0.56
|
3.08
|
2.52
|
0.96
|
1.45
|
0.4
|
1.35
|
0.77
|
1.69
|
1.72
|
1.73
| |||
C26:0/C22:0, ratio | 0.03–0.07 |
0.25
|
0.45
| 0.05 |
0.52
|
0.29
|
0.12
|
1.02
|
0.7
|
0.23
|
0.28
|
0.12
|
0.47
|
0.28
|
0.31
|
0.59
|
0.47
| |||
C26:0β-oxidation, pmol/(h*mg protein) | 1214–1508 |
424
| 2069 |
213
|
482
|
836
|
581
|
722
|
489
|
399
|
1118
|
714
|
322
|
671
|
3
|
317
| ||||
Pristanic acid β-oxidation, pmol/(h*mg protein) | 675–1121 |
9
| 736 |
57
|
27
|
107
|
171
|
131
|
37
|
61
|
430
|
178
|
32
|
118
|
1
|
17
| ||||
Phytanic acid α-oxidation, pmol/(h*mg protein) | 44–82 |
40
|
6
|
4
|
13
|
8
|
11
|
7
|
31
|
3
|
8
|
1
| ||||||||
DHAPAT activity, nmol/(2 h*mg protein) | 5.8–12.3 |
1.2
|
3.5
| 12 |
1.5
|
2
|
4.3
|
4.8
|
2.8
|
3.3
| 6.2 | 8.4 |
1.72
|
2.9
|
0.7
|
2
|
1.6
|
2
|
2.5
| |
Catalase immunofluorescence | punctate | mosaic | mosaic | punctate | enlarged | mosaic | enlarged | enlarged | enlarged | diffuse | mosaic | diffuse | diffuse | enlarged | diffuse |